Mahender Nayak swaps Dubai for Singapore, becomes Takeda APAC Lead
Japanese giant Takeda has a new Head for APAC; Indian national Dr Mahender Nayak, previously the firm’s India, CIS, Middle East, Turkey & Africa (ICMEA) lead. Nayak will relocate to…
Address: 41 Science Park Road, #04-03B The Gemini,Singapore Science Park II,Singapore 117610,Singapore
Tel: +(65) 6829-5600
Web: http://www.merlionpharma.com/
MerLion Pharmaceuticals Pte Ltd was formed in 2002 through the privatisation of the former Centre for Natural Product Research (CNPR), a unique unit of Singapore’s Institute of Molecular and Cell Biology (IMCB). MerLion Pharma acquired all of CNPR’s assets, including its unique collection of natural product samples. The company is now focused on developing its lead antibacterial candidate, finafloxacin.
MerLion Pharma is progressing finafloxacin, a novel, highly differentiated antibacterial candidate. The compound, which has already shown potential for the treatment of urinary tract infections and the eradication of Helicobacter pylori, is being evaluated in critical care and hospital indications
Japanese giant Takeda has a new Head for APAC; Indian national Dr Mahender Nayak, previously the firm’s India, CIS, Middle East, Turkey & Africa (ICMEA) lead. Nayak will relocate to…
The latest healthcare and pharma news from Singapore, including the partnership between Boehringer Ingelheim and A*STAR for targeted cancer therapies, Amgen’s sponsorship of biotech incubator, NSG BioLabs, and Tessa Therapeutics’…
The latest pharma news from Southeast Asia, including the Singaporean Health Sciences Authority (HSA) being awarded the highest maturity level in the WHO’s classification of global regulatory authorities, as well…
Stewart Campbell, Vice President and General Manager, Asia Pacific, West Pharmaceutical Services, highlights how the drug containment and delivery system industry is evolving to meet the rapidly changing needs of…
To cater to Japan and Asia Pacific (JAPAC)’s booming biotech industry, in May 2021 IQVIA expanded its ‘IQVIA Biotech’ brand into the region. Looking ahead to 2022, IQVIA Biotech JAPAC…
Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for…
Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical…
Angeline Ho gives an overview of the patient advocacy landscape in Asia-Pacific, why an Asian model of patient engagement – distinct from those in Europe and the US – needs…
The Asia-Pacific (APAC) region is home to around 1.44 billion people, over 60 percent of the world’s population, and a vast diversity of cultures, infrastructures, and economic development. Managing a…
Ashish Mahajan, Partner in Deloitte’s Life Sciences and Healthcare Consulting Practice in Southeast Asia, outlines some of the key trends playing out in the region, the extent to which the…
Professor Subra Suresh, president of Nanyang Technological University (NTU) and former director of the US National Science Foundation, explains how the university has managed to consistently be among the top…
Marco Lee, APAC head for medical device firm Avanos explains how the company’s products are catered to patient needs in the region and talks through key growth drivers, the impact…
See our Cookie Privacy Policy Here
